Free tool
FAERS Monitor: Rybrevant Faspro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761433 or its brand name (Rybrevant Faspro, Amivantamab and Hyaluronidase-Lpuj). Reports on generic versions are filed under their own applications.
Reports
306
Serious
207
68% of reports
Hospitalization
49
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- rash47
- infusion related reaction32
- paronychia29
- off label use22
- nausea17
- stomatitis17
- pyrexia14
- administration related reaction13
- decreased appetite13
- pruritus12
- cytopenia11
- fatigue11
- malaise11
- neutrophil count decreased11
- skin disorder11
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 305 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,853 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| administration related reactionSignal | 13 | 4914.5 | 2831.4 | 55,108 |
| paronychiaSignal | 29 | 456.6 | 322.5 | 12,650 |
| cytopeniaSignal | 11 | 61.8 | 34.6 | 598 |
| infusion related reactionSignal | 32 | 33.2 | 23.9 | 970 |
| skin disorderSignal | 11 | 22.7 | 12.7 | 207 |
| stomatitisSignal | 17 | 19.3 | 12.1 | 277 |
| neutrophil count decreasedSignal | 11 | 18.6 | 10.4 | 166 |
| rashSignal | 47 | 7.4 | 5.7 | 260 |
| decreased appetiteSignal | 13 | 3.8 | 2.3 | 25 |
| pyrexiaSignal | 14 | 2.8 | 1.7 | 14 |
| pruritusSignal | 12 | 2.1 | 1.2 | 6 |
| off label use | 22 | 1.7 | 1.2 | 6 |
| malaise | 11 | 1.7 | 1.0 | 3 |
| nausea | 17 | 1.5 | 0.9 | 2 |
| fatigue | 11 | 1.0 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.